167 related articles for article (PubMed ID: 23299198)
1. C-kit-mutated melanomas: the Chinese experience.
Si L; Guo J
Curr Opin Oncol; 2013 Mar; 25(2):160-5. PubMed ID: 23299198
[TBL] [Abstract][Full Text] [Related]
2. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
3. KIT as a therapeutic target in metastatic melanoma.
Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
[TBL] [Abstract][Full Text] [Related]
4. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
5. Repurposing Ponatinib as a Potent Agent against
Han Y; Gu Z; Wu J; Huang X; Zhou R; Shi C; Tao W; Wang L; Wang Y; Zhou G; Li J; Zhang Z; Sun S
Theranostics; 2019; 9(7):1952-1964. PubMed ID: 31037149
[No Abstract] [Full Text] [Related]
6. A potential role for nilotinib in KIT-mutated melanoma.
Tran A; Tawbi HA
Expert Opin Investig Drugs; 2012 Jun; 21(6):861-9. PubMed ID: 22500535
[TBL] [Abstract][Full Text] [Related]
7. KIT and Melanoma: Biological Insights and Clinical Implications.
Pham DDM; Guhan S; Tsao H
Yonsei Med J; 2020 Jul; 61(7):562-571. PubMed ID: 32608199
[TBL] [Abstract][Full Text] [Related]
8. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
9. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
10. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
11. Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
Kong Y; Si L; Zhu Y; Xu X; Corless CL; Flaherty KT; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lu A; Guo J
Clin Cancer Res; 2011 Apr; 17(7):1684-91. PubMed ID: 21325067
[TBL] [Abstract][Full Text] [Related]
12. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
[TBL] [Abstract][Full Text] [Related]
13. [New therapies targeting the genetic mutations responsible for different types of melanoma].
Botella-Estrada R; Sanmartín Jiménez O
Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases.
Terada T
Int J Clin Oncol; 2010 Oct; 15(5):453-6. PubMed ID: 20425130
[TBL] [Abstract][Full Text] [Related]
15. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
[TBL] [Abstract][Full Text] [Related]
16. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
17. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
18.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
19. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
Ashida A; Takata M; Murata H; Kido K; Saida T
Int J Cancer; 2009 Feb; 124(4):862-8. PubMed ID: 19035443
[TBL] [Abstract][Full Text] [Related]
20. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]